Experience

CellCentric

• United Kingdom
• Biotechnology
• 1 - 100 Employee

• Director of Cancer Biology

  • Apr 2022 - 1 year 9 months

  Manchester, England, United Kingdom



Cancer Research UK Manchester Institute

• United Kingdom
• Research Services
• 100 - 200 Employee

• Associate Scientist

  • 2015 - Apr 2022

  Manchester, United Kingdom Co-lead for the Preclinical Pharmacology Team within the CRUK Manchester Institute Cancer Biomarker Centre. This team of 25 researchers, consisting of postdoctoral scientists, graduate students, and technicians, develops and utilises preclinical models to investigate the biology of cancer, with a particular focus on lung cancer. Liaising with clinicians, academics, biotech, and pharma, we strive to facilitate biomarker-driven precision medicine approaches for improved patient… Show more Co-lead for the Preclinical Pharmacology Team within the CRUK Manchester Institute Cancer Biomarker Centre. This team of 25 researchers, consisting of postdoctoral scientists, graduate students, and technicians, develops and utilises preclinical models to investigate the biology of cancer, with a particular focus on lung cancer. Liaising with clinicians, academics, biotech, and pharma, we strive to facilitate biomarker-driven precision medicine approaches for improved patient outcomes. I am the Manchester lead for the CRUK Lung Cancer Centre of Excellence Animal Modelling Core, whose remit is to generate, characterize, and distribute patient-derived models of lung cancer. Additionally, I am the BRC Cancer Precision Medicine Advanced Cultures lead in charge of generating primary cultures from solid and liquid biopsies. Show less



Ontario Cancer Institute

• Biotechnology
• 1 - 100 Employee

• Postdoctoral Researcher

  • 2013 - 2015

  Toronto, Canada Area Leveraging my experience utilising mouse models of cancer and the extensive biobank of patient-derived xenografts at the PMCC, I investigated the role for the SWI/SNF chromatin remodelling complex in pancreatobiliary cancer, with a focus on identifying therapeutic vulnerabilities in ARID1A-mutant tumors.



Cancer Research UK Cambridge Institute

• United Kingdom
• Research
• 100 - 200 Employee

• Postdoctoral fellow

  • 2006 - 2012

  Cambridge, United Kingdom In the lab of David Tuveson, I exploited genetically engineered mouse models of pancreatic cancer to investigate molecular mechanisms of metastasis, as well as interrogate the therapeutic efficacy of several novel, clinically relevant compounds. To complement these studies, I developed and characterized a genetically-modifiable syngeneic model of pancreatic cancer suitable for high throughput studies in an immune-competent environment.